The Mystery in the Rye

There are countless reports on microorganisms and their special abilities. The saga of the ergot fungus is perhaps the most unusual of them all. The unique history of this plant pathogenic microbe, which began with its infection of grasses, is told through a broad storyline that stretches from the early medical writings of Mesopotamia, Greece, and China, to the industrial and academic laboratories of pharmaceutical research in the 21st century....

Among cultivated grasses, the ergot fungus mainly infests rye. Its overwintering structure, the black-purple ergot kernel, grows out of the ears of the grain. The highly active substances it contains caused mass poisonings in Europe over a period of 1,000 years, in the course of which the victims suffered from terrible symptoms of illness. Only in the 17th century, doctors recognized ergot as the corpus delicti for the regularly recurring waves of mass poisoning. The development of drugs from pure ergot compounds is one of the fascinating contributions of pharmaceutical natural product and medicinal chemistry and was of great importance for the modernization of medicine. A straight line can be drawn from this research to the synthesis of LSD, whose accidentally observed psychotropic effect revealed the chemical basis of the psyche. In combination with other centrally active substances, the LSD studies opened the therapeutic research field of psychopharmacology.

The ergot fungus stands for legendary advances in pharmaceutical science and human therapy. At the same time, the people who investigated this unique microorganism scientifically, for a wide variety of reasons, became part of its cultural history. Throughout the centuries, they have kept the wheels turning - an innovative power which is still effective today.

A thrilling journey of discovery through history the development of the hallucinogen from diesease to drug new pieces in the puzzle of the history of ergotism

Autorentext

Frank Petersen studied biology at the universities of Stuttgart-Hohenheim and Tübingen and has been the Head of the Natural Product department at the pharmaceutical company Novartis AG in Basel for many years. In his pharmaceutical research, the internationally renowned scientist focuses on the discovery, genetics, and production of novel active substances from fungi, bacteria, and plants as potential new therapeutics. In the context of implementing the "Convention on Biological Diversity", he has advised working groups at the European Union, the Swiss Federal Assembly, the German Federal Government, the World Trade Organization, and the United Nations. Invitations to guest professorships have taken him to Seoul, Korea, and Shanghai, China. For his contributions to microbial natural product research, he was awarded the "Senior Industrial Science Award 2020" by the Swiss Chemical Society. He is a member of the advisory board of "Swiss Youth in Science" and chairs the advisory committee of the Novartis Pavillon Basel.

Inhalt

Chapter1.- Chapter2.- Chapter3.- Chapter4.- Chapter5.- Chapter6.- Chapter7.- Chapter8.- Chapter9.- Chpater10.